SourcingLink.net Signs a Letter of Intent with NanoSmart Pharmaceuticals, Inc. for a Licensee and Co-Development Collaboratio...
February 26 2019 - 4:37PM
InvestorsHub NewsWire
San Francisco, CA -- February 26, 2019 -- InvestorsHub
NewsWire -- SourcingLink.net (OTC PINK: SNET), an early stage
oncology company, is a pioneering company based in San Francisco,
California, USA. The company announced today that it signed a
Letter of Intent to collaborate with NanoSmart Pharmaceuticals,
Inc., a California-based company developing novel drug formulations
to treat cancer. The collaboration includes co-development and an
exclusive, world-wide license for specific formulations to treat
cancer utilizing NanoSmart's proprietary ‘targeted’ drug delivery
system that is designed to enhance delivery of drugs to a wide
variety of cancer tumors.
SourcingLink.net is excited about the collaboration opportunity
because new or already-approved chemotherapy drugs can be
reformulated with greater efficacy and safety for treating cancer
patients. The company believes that the reformulated drugs, subject
to approval by the FDA and/or regional regulatory bodies, may be
used as a monotherapy, or as a ‘combo-therapy’ with SNET’s
autologous cellular immuno-therapy approach, or with other
therapies such as immune check point inhibitors. SNET expects to
enter into a full exclusive ‘world-wide’ licensing and
co-development agreement with NanoSmart under the terms of the
Letter of Intent signed on February 25th, 2019.
The use of NanoSmart's enhanced drug delivery platform combined
with pharmacogenomics and liquid biopsy for personalizing the
therapy should augment cancer drug effectiveness and safety, and
improve treatment monitoring, according to the company. Currently,
SNET is focused on developing its ‘core’ autologous extracorporeal
immuno-therapy device for a durable response.
About SourcingLink.net:
SourcingLink.net, Inc. ("SNET") is a pioneering oncology
company dedicated to developing , manufacturing and
commercialization of therapeutics. SNET licensed Tulynode's patent
pending Autologous Immuno-therapy for durable therapy response
using an extracorporeal device.
SourcingLink.net prides itself for having a world-class
Advisory Board that keeps the Company leadership in the forefront
of developing technologies in cancer research, biotechnology
and healthcare. SourcingLink.net is currently engaging in
research and development of therapeutics for oncology.
SourcingLink.net is committed to its core corporate mission
and values of highest U.S. Pharma Code of Conduct standards of
behavior for being in compliance with the laws, regulations,
company directives and guidance.
Forward-looking Statements:
This release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements, which contain words such as
“expect”, “believe” or “plan”, by their nature address matters that
are, to different degrees, uncertain. These uncertainties may
cause actual future events to be materially different than those
expressed in our forward-looking statements. We do not
undertake to update our forward-looking statements.
Source: SourcingLink.net, Inc.
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
email: info@sourcinglink.net
website: www.sourcinglink.net